The expansion of GLP-1 availability through direct-to-consumer telehealth platforms increases prescribing competition and patient access pathways outside traditional primary care settings, necessitating that family physicians establish robust protocols for identifying patients already engaged in telehealth GLP-1 therapy during routine visits. This fragmentation of GLP-1 care delivery across multiple platforms requires family physicians to actively screen for concurrent GLP-1 use, medication interactions, and appropriate monitoring parameters that may not be coordinated across providers. Understanding the competitive telehealth landscape is clinically essential for family physicians to maintain continuity of care, prevent duplicative prescribing, and ensure patients receiving GLP-1 therapy through alternative channels still access appropriate cardiovascular risk assessment, gastrointestinal symptom monitoring, and metabolic follow-up.

The expansion of telehealth platforms to include all FDA-approved GLP-1 receptor agonists represents a significant shift in treatment accessibility for obesity and related metabolic conditions. This integration by Him and Hers now encompasses the full spectrum of currently approved agents, including semaglutide formulations (Wegovy for obesity, Ozempic for type 2 diabetes), tirzepatide (Zepbound for obesity, Mounjaro for type 2 diabetes), and other FDA-approved GLP-1 therapies. This development reflects the growing recognition of obesity as a chronic disease requiring ongoing pharmacotherapy and the increasing demand for convenient, scalable delivery mechanisms in primary care settings.

The clinical significance of this platform consolidation lies in reducing barriers to initiation and maintenance therapy for patients who might otherwise face delays or obstacles in accessing these medications through traditional in-office visits. By offering multiple agents with different mechanisms of action and pharmacokinetic profiles, prescribers using this telehealth model can now implement dose escalation protocols, manage side effect profiles with agent switching, and provide continuity of care without requiring in-person evaluation for routine medication management. This approach aligns with evidence supporting remote monitoring of GLP-1 therapy, where vital signs, symptom assessment, and laboratory parameters can be systematically tracked between provider encounters.

For practicing physicians, this expansion increases the practical options for prescribing GLP-1 therapy within established telehealth workflows, potentially streamlining patient access while maintaining clinical oversight. The availability of multiple agents on a single platform facilitates comparative prescribing decisions based on individual patient factors, including baseline glycemic control, comorbidities, and previous medication trials, without requiring referral to separate providers or pharmacy systems.

Clinical Takeaway:

Telehealth platforms are expanding access to all FDA-approved GLP-1 medications, making these therapies more readily available to patients in family medicine settings. This increased accessibility means clinicians should establish clear screening protocols to identify appropriate candidates based on BMI, comorbidities, and contraindications rather than relying on convenience of availability. GLP-1 therapy requires ongoing monitoring for gastrointestinal side effects, weight loss progression, and metabolic changes, which remains the family physician’s responsibility regardless of prescribing source. When counseling patients about telehealth GLP-1 options, emphasize that remote prescribing still requires baseline clinical evaluation and that your office provides continuity of care for medication management, side effect mitigation, and assessment of therapeutic goals over time.

“I see Him & Hers bringing all the major GLP-1 options into their telehealth platform, which reflects the market reality that patients now expect choice and accessibility in this therapeutic class. What’s clinically important here is that expanded platform access doesn’t replace the need for thoughtful patient selection and metabolic assessment before initiation, something that requires real physician judgment and not just algorithmic matching. The key patient communication implication is that your patients may already be exploring these services, so you need to be proactive about discussing GLP-1 therapy in your practice rather than waiting for them to seek it elsewhere. My stance remains that telehealth can absolutely democratize access to these medications, but only when it’s paired with adequate screening for contraindications, baseline glycemic status, and realistic goal-setting about what these agents can and cannot do.”

? Join the Conversation

Have a question about how this applies to your situation? Ask Dr. Caplan →

Want to discuss this topic with other patients and caregivers? Join the forum discussion →

Have thoughts on this? Share it: